The immunological consequences of TGFβ antagonism are particularly relevant in the context of anti-tumor immunotherapy, and blockade of the TGFβ pathway has become an attractive approach to inhibit the multitude effects the TGFβ pathway has on cancer progression and anti-tumor immunity. The gene discussed is TGFB1; the disease is cancer.